Table 2.

Disease severity scores at apremilast treatment initiation and 6 (± 1) months (patients with non-missing data)

	At apremilast initiation		At 6 (± 1) months
	N	Median (IQR)	N	Median (IQR)
BSA (%)	137	10.0 (5.0–16.0)	157	4.0 (1.0–6.0)
PGA (0–4 scale)	66	3.0 (3.0–3.0)	85	1.0 (0.0–2.0)
PGA (0–5 scale)	44	3.0 (3.0–4.0)	47	2.0 (1.0–2.0)
PGA (0–6 scale)	4	5.0 (5.0–5.5)	1	1.0
PASI	166	11.0 (8.0–16.0)	NA	NA

N number of patients with non-missing data, NA not available (not collected according to the study protocol), IQR interquartile range, BSA body surface area, PASI Psoriasis Area and Severity Index, PGA Physician Global Assessment